JP2022549171A5 - - Google Patents
Info
- Publication number
- JP2022549171A5 JP2022549171A5 JP2022517446A JP2022517446A JP2022549171A5 JP 2022549171 A5 JP2022549171 A5 JP 2022549171A5 JP 2022517446 A JP2022517446 A JP 2022517446A JP 2022517446 A JP2022517446 A JP 2022517446A JP 2022549171 A5 JP2022549171 A5 JP 2022549171A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocycloalkyl
- cycloalkyl
- member heterocycloalkyl
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910892032 | 2019-09-20 | ||
| CN201910892032.X | 2019-09-20 | ||
| CN201911129688.2 | 2019-11-18 | ||
| CN201911129688 | 2019-11-18 | ||
| CN201911157939 | 2019-11-22 | ||
| CN201911157939.8 | 2019-11-22 | ||
| CN202010054188 | 2020-01-17 | ||
| CN202010054188.3 | 2020-01-17 | ||
| CN202010102546 | 2020-02-19 | ||
| CN202010102546.3 | 2020-02-19 | ||
| CN202010230303 | 2020-03-27 | ||
| CN202010230303.8 | 2020-03-27 | ||
| CN202010306926.9 | 2020-04-17 | ||
| CN202010306926 | 2020-04-17 | ||
| CN202010367694 | 2020-04-30 | ||
| CN202010367694.8 | 2020-04-30 | ||
| CN202010967317.8 | 2020-09-15 | ||
| CN202010967317 | 2020-09-15 | ||
| PCT/CN2020/116510 WO2021052499A1 (zh) | 2019-09-20 | 2020-09-21 | 稠合吡啶酮类化合物及其制备方法和应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022549171A JP2022549171A (ja) | 2022-11-24 |
| JP2022549171A5 true JP2022549171A5 (cg-RX-API-DMAC10.html) | 2023-09-28 |
| JP7642619B2 JP7642619B2 (ja) | 2025-03-10 |
Family
ID=74883935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517446A Active JP7642619B2 (ja) | 2019-09-20 | 2020-09-21 | 縮合ピリドン化合物、ならびにその調製方法および使用 |
Country Status (15)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| AU2019338207B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| US12377101B2 (en) | 2018-12-05 | 2025-08-05 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| ES3065954T3 (en) | 2019-05-13 | 2026-05-08 | Relay Therapeutics Inc | Fgfr inhibitors and methods of use thereof |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| MD4051678T2 (en) | 2019-10-28 | 2026-07-31 | Merck Sharp & Dohme Llc | Small molecule inhibitors of the KRAS G12C mutant |
| BR112022008375A2 (pt) * | 2019-10-30 | 2022-07-12 | Genfleet Therapeutics Shanghai Inc | Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| AU2021248363B2 (en) * | 2020-04-03 | 2024-02-15 | Medshine Discovery Inc. | Octahydropyrazinodiazanaphthyridine dione compounds |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| US12655160B2 (en) | 2020-08-04 | 2026-06-16 | Mirati Therapeutics, Inc. | KRAS G12D inhibitors |
| CN116406363B (zh) * | 2020-08-21 | 2025-06-20 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法及其医药上的用途 |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| EP4216951B1 (en) | 2020-09-22 | 2026-04-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| TWI924727B (zh) | 2020-11-18 | 2026-05-11 | 美商傳達治療有限公司 | Ｆｇｆｒ抑制劑及其製造及使用方法 |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| CN116670136A (zh) * | 2020-12-31 | 2023-08-29 | 正大天晴药业集团股份有限公司 | 四环类化合物及其医药用途 |
| CN116964056B (zh) * | 2021-03-25 | 2026-04-10 | 上海济煜医药科技股份有限公司 | 稠合吡啶酮类化合物盐型、晶型及其应用 |
| CN115124533A (zh) * | 2021-03-26 | 2022-09-30 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法和其医药上的用途 |
| WO2022198904A1 (zh) * | 2021-03-26 | 2022-09-29 | 浙江海正药业股份有限公司 | 一种kras抑制剂关键中间体及其制备方法 |
| WO2022206723A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| WO2022223037A1 (zh) * | 2021-04-22 | 2022-10-27 | 劲方医药科技(上海)有限公司 | Kras抑制剂的盐或多晶型物 |
| CA3226720A1 (en) * | 2021-07-23 | 2023-01-26 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| CN117222654A (zh) * | 2021-09-06 | 2023-12-12 | 苏州赞荣医药科技有限公司 | Kras g12c抑制剂和其用途 |
| WO2023116895A1 (zh) * | 2021-12-24 | 2023-06-29 | 劲方医药科技(上海)有限公司 | Kras抑制剂的多晶型物及其制备方法和用途 |
| CN116327956B (zh) * | 2022-04-01 | 2025-11-28 | 劲方医药科技(上海)股份有限公司 | 药物组合物、其用途及癌症的治疗方法 |
| CN119998295A (zh) | 2022-06-08 | 2025-05-13 | 因赛特公司 | 作为dgk抑制剂的三环三唑并化合物 |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US20260137665A1 (en) | 2022-10-11 | 2026-05-21 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| CN121013721A (zh) * | 2022-11-23 | 2025-11-25 | 沪亚生物国际有限公司 | 包含kras抑制剂和sph2抑制剂的组合疗法 |
| WO2025016436A1 (zh) * | 2023-07-19 | 2025-01-23 | 上海济煜医药科技有限公司 | Kras抑制剂的制备方法、其中间体和其中间体的制备方法 |
| WO2025036442A1 (zh) * | 2023-08-15 | 2025-02-20 | 劲方医药科技(上海)股份有限公司 | 吡嗪并萘啶二酮类化合物的制备方法及其中间体 |
| KR20260104082A (ko) | 2023-09-29 | 2026-07-03 | 디3 바이오 (우씨) 컴퍼니, 리미티드 | 암의 치료에 사용하기 위한 wx-001 또는 그의 유도체와 kras g12c 억제제의 조합물 |
| KR20260096846A (ko) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
| WO2025256521A1 (zh) * | 2024-06-11 | 2025-12-18 | 上海济煜医药科技有限公司 | 作为kras抑制剂的稠合吡啶酮类化合物的制备方法、中间体及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX380928B (es) | 2013-10-10 | 2025-03-12 | Araxes Pharma Llc | Inhibidores de kras g12c. |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| AU2016245864C1 (en) * | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| ES2856880T3 (es) * | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
| RU2722149C1 (ru) * | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| KR102932353B1 (ko) | 2015-11-16 | 2026-02-27 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| WO2017100546A1 (en) * | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2018142365A1 (en) * | 2017-02-03 | 2018-08-09 | The University Of North Carolina At Chapel Hill | Inhibitors of microbial beta-glucuronidase enzymes and uses thereof |
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| UA127968C2 (uk) * | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| US10597405B2 (en) * | 2017-12-08 | 2020-03-24 | Astrazeneca Ab | Chemical compounds |
| SG10202102462SA (en) * | 2018-01-19 | 2021-04-29 | Medshine Discovery Inc | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
| MX2020010836A (es) * | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| CN111484477B (zh) * | 2019-01-29 | 2022-07-08 | 博瑞生物医药（苏州）股份有限公司 | 一种苯并吡啶酮杂环化合物及其用途 |
| CN113396147B (zh) * | 2019-05-31 | 2024-06-18 | 上海翰森生物医药科技有限公司 | 芳香杂环类衍生物调节剂、其制备方法和应用 |
| CN112300194B (zh) * | 2019-07-30 | 2022-01-14 | 上海凌达生物医药有限公司 | 一类稠环吡啶酮类化合物、制备方法和用途 |
| BR112022008375A2 (pt) * | 2019-10-30 | 2022-07-12 | Genfleet Therapeutics Shanghai Inc | Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste |
-
2020
- 2020-09-21 CN CN202310905052.2A patent/CN116947885B/zh active Active
- 2020-09-21 JP JP2022517446A patent/JP7642619B2/ja active Active
- 2020-09-21 EP EP20865331.1A patent/EP4043464A4/en active Pending
- 2020-09-21 WO PCT/CN2020/116510 patent/WO2021052499A1/zh not_active Ceased
- 2020-09-21 MX MX2022003401A patent/MX2022003401A/es unknown
- 2020-09-21 AU AU2020350745A patent/AU2020350745B2/en active Active
- 2020-09-21 KR KR1020227013103A patent/KR102984049B1/ko active Active
- 2020-09-21 PH PH1/2022/550681A patent/PH12022550681A1/en unknown
- 2020-09-21 CN CN202410656034.XA patent/CN118619971A/zh active Pending
- 2020-09-21 TW TW109132517A patent/TWI761961B/zh active
- 2020-09-21 CN CN202411842480.6A patent/CN119462689A/zh active Pending
- 2020-09-21 BR BR112022005193A patent/BR112022005193A2/pt unknown
- 2020-09-21 US US17/761,983 patent/US20220389029A1/en active Pending
- 2020-09-21 CN CN202080078771.6A patent/CN114728968B/zh active Active
- 2020-09-21 CA CA3155066A patent/CA3155066A1/en active Pending
- 2020-09-21 CN CN202411842482.5A patent/CN119591618A/zh active Pending
-
2022
- 2022-03-17 IL IL291467A patent/IL291467B2/en unknown
- 2022-03-18 CL CL2022000666A patent/CL2022000666A1/es unknown
- 2022-04-12 CO CONC2022/0004686A patent/CO2022004686A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022543767A5 (cg-RX-API-DMAC10.html) | ||
| TWI864048B (zh) | 抗病毒雜環化合物、其醫藥組成物及其用途 | |
| CN101268073B (zh) | 杂环化合物、制备方法及其用途 | |
| CN108218873B (zh) | 流感病毒复制抑制剂及其用途 | |
| CN107312009B (zh) | 喹啉类化合物、其制备方法、中间体、药物组合物和应用 | |
| CN110582500B (zh) | 双并环类核衣壳抑制剂和其作为药物用于治疗乙型肝炎的用途 | |
| WO2019154366A1 (zh) | 含氮杂环类化合物及其制备方法和用途 | |
| CN103124730A (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
| JP2002535331A (ja) | 新規血管形成阻害薬 | |
| JP2008514643A5 (cg-RX-API-DMAC10.html) | ||
| JP2013536235A5 (cg-RX-API-DMAC10.html) | ||
| JP7530510B2 (ja) | Ｒｎａヘリカーゼｄｈｘ３３を阻害する多環式化合物及びその応用 | |
| US8399668B2 (en) | Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides | |
| TW202024093A (zh) | 作為抗病毒劑之官能化雜環 | |
| TW201741303A (zh) | 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途 | |
| CN105473573A (zh) | 用作激酶抑制剂的咔唑甲酰胺化合物 | |
| TWI424998B (zh) | 作為腺苷A3受體配體的三唑并[1,5-a]喹啉類 | |
| CN115073450A (zh) | Krasg12c突变蛋白抑制剂的制备及其应用 | |
| TW201242955A (en) | Nitrogen-containing heterocyclic compound | |
| AU2021342777A1 (en) | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | |
| WO2021121420A1 (zh) | 苯并吡唑类化合物及其中间体、制备方法和应用 | |
| WO2023088425A1 (zh) | 15-pgdh抑制剂及用途 | |
| TW201124411A (en) | The manufacturing method of 6-substituted-1-methy-1H-benzimidazol derivatives and the synthesis intermediates thereof | |
| WO2025040014A1 (zh) | 并环化合物及其制备方法和用途 | |
| WO2024036183A1 (en) | Antagonists of 5-hydroxytryptamine receptor subtype 2b |